These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 12692043)

  • 1. Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus.
    Doak SH; Jenkins GJ; Parry EM; D'Souza FR; Griffiths AP; Toffazal N; Shah V; Baxter JN; Parry JM
    Gut; 2003 May; 52(5):623-8. PubMed ID: 12692043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
    Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
    Galipeau PC; Prevo LJ; Sanchez CA; Longton GM; Reid BJ
    J Natl Cancer Inst; 1999 Dec; 91(24):2087-95. PubMed ID: 10601379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence.
    Walch AK; Zitzelsberger HF; Bruch J; Keller G; Angermeier D; Aubele MM; Mueller J; Stein H; Braselmann H; Siewert JR; Höfler H; Werner M
    Am J Pathol; 2000 Feb; 156(2):555-66. PubMed ID: 10666385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular evaluation of ablative therapy of Barrett's oesophagus.
    Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
    J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry.
    Krishnadath KK; Tilanus HW; Alers JC; Mulder AH; van Dekken H
    Cytometry; 1994 Feb; 15(2):176-84. PubMed ID: 8168405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic alterations in malignant transformation of Barrett's esophagus.
    Riegman PH; Vissers KJ; Alers JC; Geelen E; Hop WC; Tilanus HW; van Dekken H
    Cancer Res; 2001 Apr; 61(7):3164-70. PubMed ID: 11306503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma.
    González MV; Artímez ML; Rodrigo L; López-Larrea C; Menéndez MJ; Alvarez V; Pérez R; Fresno MF; Pérez MJ; Sampedro A; Coto E
    J Clin Pathol; 1997 Mar; 50(3):212-7. PubMed ID: 9155671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the premalignant stages of Barrett's oesophagus through to adenocarcinoma by comparative genomic hybridization.
    Croft J; Parry EM; Jenkins GJ; Doak SH; Baxter JN; Griffiths AP; Brown TH; Parry JM
    Eur J Gastroenterol Hepatol; 2002 Nov; 14(11):1179-86. PubMed ID: 12439111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of locus-specific probes for interphase fluorescence in situ hybridisation--application in Barrett's esophagus.
    Doak SH; Saidely D; Jenkins GJ; Parry EM; Griffiths AP; Baxter JN; Parry JM
    Exp Mol Pathol; 2004 Aug; 77(1):26-33. PubMed ID: 15215047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma.
    Brankley SM; Fritcher EG; Smyrk TC; Keeney ME; Campion MB; Voss JS; Clayton AC; Wang KK; Lutzke LS; Kipp BR; Halling KC
    Hum Pathol; 2012 Feb; 43(2):172-9. PubMed ID: 21820152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biology of Barrett's adenocarcinoma.
    Wijnhoven BP; Tilanus HW; Dinjens WN
    Ann Surg; 2001 Mar; 233(3):322-37. PubMed ID: 11224619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus.
    Trautmann B; Wittekind C; Strobel D; Meixner H; Keymling J; Gossner L; Ell C; Hahn EG
    Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):799-804. PubMed ID: 8864678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
    Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS
    Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromosomal numerical aberrations are frequent in oesophageal and gastric adenocarcinomas: a study using in-situ hybridization.
    Beuzen F; Dubois S; Fléjou JF
    Histopathology; 2000 Sep; 37(3):241-9. PubMed ID: 10971700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.
    Chao DL; Maley CC; Wu X; Farrow DC; Galipeau PC; Sanchez CA; Paulson TG; Rabinovitch PS; Reid BJ; Spitz MR; Vaughan TL
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1935-40. PubMed ID: 17035402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecular biology of esophageal adenocarcinoma.
    Koppert LB; Wijnhoven BP; van Dekken H; Tilanus HW; Dinjens WN
    J Surg Oncol; 2005 Dec; 92(3):169-90. PubMed ID: 16299787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma.
    Snider EJ; Compres G; Freedberg DE; Khiabanian H; Nobel YR; Stump S; Uhlemann AC; Lightdale CJ; Abrams JA
    Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1687-1693. PubMed ID: 31466948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stepwise radical endoscopic resection of the complete Barrett's esophagus with early neoplasia successfully eradicates pre-existing genetic abnormalities.
    Peters FP; Krishnadath KK; Rygiel AM; Curvers WL; Rosmolen WD; Fockens P; Ten Kate FJ; van Baal JW; Bergman JJ
    Am J Gastroenterol; 2007 Sep; 102(9):1853-61. PubMed ID: 17509033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.